-+ 0.00%
-+ 0.00%
-+ 0.00%
Need To Know: The Consensus Just Cut Its 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Estimates For 2027
Share
Listen to the news

The latest analyst coverage could presage a bad day for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

Following the downgrade, the consensus from eight analysts covering 4D Molecular Therapeutics is for revenues of US$17m in 2027, implying a concerning 82% decline in sales compared to the last 12 months. Losses are expected to increase substantially, hitting US$4.12 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$21m and losses of US$4.00 per share in 2027. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.

View our latest analysis for 4D Molecular Therapeutics

earnings-and-revenue-growth
NasdaqGS:FDMT Earnings and Revenue Growth November 20th 2026

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 75% by the end of 2027. This indicates a significant reduction from annual growth of 54% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 21% per year. It's pretty clear that 4D Molecular Therapeutics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses next year, suggesting all may not be well at 4D Molecular Therapeutics. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on 4D Molecular Therapeutics after today.

There might be good reason for analyst bearishness towards 4D Molecular Therapeutics, like a short cash runway. Learn more, and discover the 1 other flag we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending